Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+3.94%
+21.47%
+3.35%
+1.19%
-0.30%
Most Trending
+3.94%
+21.47%
+3.35%
+1.19%
-0.30%
Top.GainersTop.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
20 Oct 2025$NVTS Navitas Semiconductor Trading at $17.67, just above its 52-week high of $16.85. The stock is up nearly 400% this year, driven by its Gallium Nitride (GaN) and Silicon Carbide (SiC) power devices for next-generation AI data centers. RSI at 85.27 shows extreme bullish momentum, though traders should watch for potential pullbacks at these overbought levels.
$CLF - Cleveland-Cliffs Currently at $15.94, surpassing its 52-week high of $14.51. Despite missing Q3 revenue estimates, the stock maintains an uptrend with an RSI of 73.05. Volume is lighter than average today, suggesting the breakout could use more confirmation from buyers.
$AMD Advanced Micro Devices Trading at $242.37, above its 52-week high of $241.20. The stock appears on Wall Street's most overbought list with an RSI of 73.92. Volume is significantly below average today, which could indicate profit-taking ahead.
$MU Micron Technology Hitting $208.99, surpassing the 52-week high of $206.34. RSI at 72.01 signals overbought conditions. Traders should monitor whether buying pressure can sustain these levels or if a consolidation period is due.
$CELC Celcuity Impressive move to $75.90, well above its 52-week high of $63.06. The biotech is getting attention after completing enrollment for its PIK3CA mutant cohort in a Phase 3 trial and presenting positive data at the ESMO Congress. Volume is more than 3x average, confirming strong institutional interest.
$GRAL Grail Surging to $96.33, breaking past the 52-week high of $89.57. The healthcare company announced a private placement at $70.05/share for 4.6 million shares. Volume is above average, though the RSI of 76.51 suggests the move may be getting extended.
$NTRA Natera Trading at $192.60, above its 52-week high of $187.34. Phase 3 trial results showing Signatera-guided therapy improves survival in bladder cancer are driving momentum. RSI at 72.80 indicates strong but potentially overbought conditions.
Remember: Breakouts need volume and follow-through. Always use proper risk management and don't chase extended moves.
Join StocksRunner.com for daily market updates, expert analyses, and actionable insights.
Signup now for FREE and stay ahead of the market curve!
Find out what 10,000+ subscribers already know.
Real-time insights for informed decisions.
Limited slots available, SignUp Now!
Please note that the content above should not be considered as investment advice or marketing. It does not take into account the personal data and requirements of any individual. This content is not a substitute for the reader's own judgment and should not be considered as advice or a recommendation for buying or selling any securities or financial products.
Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Real-time stock market updates
Expert stock analysis
Investment strategies
Top stock recommendations
Trading signals and opportunities
Discover what is happening right now and piece together the key data activity before the major news outlets catch on. Stay ahead of the trends
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
